Pharmaceutical There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug major Novartis (NOVN: VX), when the EMA's Committee for Medicinal Products for Human Use (CHMP) reported decisions made at its July meetings, recommending approval of the firm's Ilaris (canakinumab) as well as its once-daily Ultibro Breezhaler (indacaterol 85mcg/glycopyrronium 43mcg delivered dose). 29 July 2013